Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent).

Tsai TT, Ho PM, Xu S, Powers JD, Carroll NM, Shetterly SM, Maddox TM, Rumsfeld JS, Margolis K, Go AS, Magid DJ.

Circ Cardiovasc Interv. 2010 Jun 1;3(3):230-5. doi: 10.1161/CIRCINTERVENTIONS.109.919001. Epub 2010 May 4.

2.

Letter by Lozano et al regarding article, "Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent)".

Lozano I, Fernández-Cimadevilla OC, Barriales V.

Circ Cardiovasc Interv. 2010 Oct;3(5):e24; author reply e25. doi: 10.1161/CIRCINTERVENTIONS.110.958355. No abstract available.

3.

Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.

Ho PM, Tsai TT, Maddox TM, Powers JD, Carroll NM, Jackevicius C, Go AS, Margolis KL, DeFor TA, Rumsfeld JS, Magid DJ.

Circ Cardiovasc Qual Outcomes. 2010 May;3(3):261-6. doi: 10.1161/CIRCOUTCOMES.109.902031. Epub 2010 Apr 20.

4.

Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.

Ho PM, Fihn SD, Wang L, Bryson CL, Lowy E, Maynard C, Magid DJ, Peterson ED, Jesse RL, Rumsfeld JS.

Am Heart J. 2007 Nov;154(5):846-51. Epub 2007 Oct 24.

PMID:
17967588
5.

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).

Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ.

Am Heart J. 2010 Feb;159(2):284-291.e1. doi: 10.1016/j.ahj.2009.11.014.

PMID:
20152228
6.

Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.

Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.

Circ Cardiovasc Interv. 2012 Jun;5(3):372-80. doi: 10.1161/CIRCINTERVENTIONS.111.967257. Epub 2012 Jun 5.

7.

Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.

Petersen JL, Barron JJ, Hammill BG, Cziraky MJ, Anstrom KJ, Wahl PM, Eisenstein EL, Krucoff MW, Califf RM, Schulman KA, Curtis LH.

Am Heart J. 2010 Mar;159(3):462-470.e1. doi: 10.1016/j.ahj.2009.11.031.

PMID:
20211310
8.

Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).

Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E.

Am J Cardiol. 2009 Nov 15;104(10):1357-61. doi: 10.1016/j.amjcard.2009.07.002. Epub 2009 Sep 26.

PMID:
19892050
9.

High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.

Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A.

Am J Cardiovasc Drugs. 2010;10(1):29-35. doi: 10.2165/11318260-000000000-00000.

PMID:
20104932
10.

Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.

Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators.

Circ Cardiovasc Interv. 2012 Jun;5(3):381-91. doi: 10.1161/CIRCINTERVENTIONS.111.967463. Epub 2012 May 22.

11.

Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.

Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, Mansukhani P, Aharonian V, Hyett R, Shen AY.

J Am Coll Cardiol. 2008 Jun 10;51(23):2220-7. doi: 10.1016/j.jacc.2008.01.063.

12.

Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.

Calver AL, Blows LJ, Harmer S, Dawkins KD, Gray HH, Morgan JH, Simpson IA.

Am Heart J. 2000 Sep;140(3):483-91.

PMID:
10966552
13.

2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).

Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bøttcher M, Lassen JF, Krusell LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Sørensen HT, Thuesen L.

J Am Coll Cardiol. 2009 Feb 24;53(8):658-64. doi: 10.1016/j.jacc.2008.09.058.

14.

Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation.

Hayashi F, Iijima R, Nakamura M, Sugi K.

J Cardiol. 2010 Jan;55(1):34-40. doi: 10.1016/j.jjcc.2009.08.002. Epub 2009 Sep 19.

15.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.

16.

Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.

Roy P, Bonello L, Torguson R, Okabe T, Pinto Slottow TL, Steinberg DH, Kaneshige K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2009 Mar 15;103(6):801-5. doi: 10.1016/j.amjcard.2008.11.038. Epub 2009 Jan 24.

PMID:
19268735
17.

The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.

Butler MJ, Eccleston D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan A, New G, Black A, Szto G, Reid CM, Yan BP, Shaw JA, Dart AM, Duffy SJ; Melbourne Interventional Group.

Am Heart J. 2009 May;157(5):899-907. doi: 10.1016/j.ahj.2009.02.018.

PMID:
19376319
18.

Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.

Casella G, Ottani F, Pavesi PC, Sangiorgio P, Rubboli A, Galvani M, Fontanelli A, Bracchetti D.

Ital Heart J. 2003 Oct;4(10):677-84.

PMID:
14664280
19.

A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.

Han YL, Wang B, Li Y, Xu K, Wang SL, Jing QM, Wang ZL, Wang DM, Ma YY, Wang G.

Chin Med J (Engl). 2009 Apr 5;122(7):793-7.

PMID:
19493391
20.

Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.

PMID:
19041120

Supplemental Content

Support Center